Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04643327 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

Study acronym: TRIP
StatusUnknown
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 25, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Jun 2023 to Jan 2025
    • Study completion date: Dec 2023 to Dec 2025
    v4
  3. Primary completion date: Jan 2023 to Jun 2023v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2021 to Feb 9, 2021
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD patients with memory problems will be compared to PD patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in PD. This information will be useful for future clinical trials to target drugs to these brain regions.
Trial Details
NCT Number NCT04643327
Lead Sponsor The University of Queensland
Collaborators: Queensland University of Technology, Johns Hopkins University, Cleveland Clinic Lou Ruvo Center for Brain Health, Royal Brisbane and Women's Hospital
Conditions
(from sponsor)		 Parkinson Disease, Mild Cognitive Impairment, Memory Impairment
Related terms Cognitive Dysfunction, Memory Disorders, Parkinson Disease
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov